Publicaciones (284) Publicaciones de GUILLERMO QUINDOS ANDRES

2024

  1. Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model

    Microbiology spectrum, Vol. 12, Núm. 1, pp. e0208623

2023

  1. Assessing pH-dependent activities of virulence factors secreted by Candida albicans

    MicrobiologyOpen, Vol. 12, Núm. 1

  2. In Vitro and In Vivo Activity of Citral in Combination with Amphotericin B, Anidulafungin and Fluconazole against Candida auris Isolates

    Journal of Fungi, Vol. 9, Núm. 6

  3. PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 12, Núm. 6, pp. 770-782

  4. Presence and implication of Candida spp. in patients with peri-implantitis enrolled in a supportive peri-implant therapy program of the Basque Country (Spain). A case–control study

    Clinical Implant Dentistry and Related Research, Vol. 25, Núm. 5, pp. 938-947

2022

  1. In vitro and in vivo anti-Candida activity of citral in combination with fluconazole

    Journal of Oral Microbiology, Vol. 14, Núm. 1

  2. Antimicrobial Peptides with Anti-Candida Activity

    International Journal of Molecular Sciences, Vol. 23, Núm. 16

  3. Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia

    Medicina Intensiva

  4. Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia

    Medicina intensiva, Vol. 46, Núm. 8, pp. 426-435

  5. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

    Frontiers in Cellular and Infection Microbiology, Vol. 12

  6. Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

    Journal of Fungi, Vol. 8, Núm. 7

2021

  1. Candida parapsilosis colony morphotype forecasts biofilm formation of clinical isolates

    Journal of Fungi, Vol. 7, Núm. 1, pp. 1-12

  2. Candidiasis by candida glabrata, candida nivariensis and candida bracarensis in galleria mellonella: Virulence and therapeutic responses to echinocandins

    Journal of Fungi, Vol. 7, Núm. 12

  3. Development and characterization of monoolein-based liposomes of carvacrol, cinnamaldehyde, citral, or thymol with anti-candida activities

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 4

  4. Erratum: Development and characterization of monoolein-based liposomes of carvacrol, cinnamaldehyde, citral, or thymol with Anti-Candida activities (Antimicrobial Agents and Chemotherapy (2021) 65:4 (e01628-20) DOI: 10.1128/AAC.01628-20)

    Antimicrobial Agents and Chemotherapy

  5. In vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilms

    Biomedicine and Pharmacotherapy, Vol. 143

  6. In vitro interaction and killing-kinetics of amphotericin b combined with anidulafungin or caspofungin against candida auris

    Pharmaceutics, Vol. 13, Núm. 9

  7. In vitro pharmacokinetic/pharmacodynamic modelling and simulation of amphotericin b against candida auris

    Pharmaceutics, Vol. 13, Núm. 11

  8. In vitro synergistic interactions of isavuconazole and echinocandins against Candida auris

    Antibiotics, Vol. 10, Núm. 4

  9. Liposomal amphotericin B: thirty years of a highly effective therapy for the treatment of invasive mycoses

    Revista Iberoamericana de Micologia, Vol. 38, Núm. 2, pp. 39-41